Dr. Afaaf Liberty

Afaaf Liberty is a clinical researcher specializing in pediatric HIV, with a strong focus on optimizing antiretroviral therapy for infants, children, and adolescents. Her work is closely aligned with major international trials, including ODYSSEY and SMILE, contributing to evidence that has shaped global guidance on integrase inhibitor–based regimens and child-friendly formulations.

Her publications emphasize pharmacokinetics, safety, resistance, and treatment outcomes of dolutegravir-, bictegravir-, and elvitegravir-based therapies in young populations. She has demonstrated improved virological suppression and reduced resistance with integrase inhibitor strategies, while also examining neuropsychiatric safety signals and NRTI-sparing approaches in virologically suppressed youth.

Beyond antiretroviral optimization, her research addresses early infant mortality, adherence, disclosure practices, psychosocial well-being, and microbiome alterations in children living with HIV in sub-Saharan Africa. This integrated clinical and social perspective highlights her contribution to advancing both biomedical efficacy and long-term quality of life outcomes in pediatric HIV care.